PRMT5 and neoplasm: We previously demonstrated that PRMT5 inhibition by DS-437 enhances anti-tumor effects of anti-erbB2/neu monoclonal antibody targeted therapy in a drug-resistant syngeneic murine breast cancer model by inhibiting Treg function and induction of tumor immunity (11).